Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly is supported by a powerful combination of near-term commercial momentum and long-duration pipeline optionality, highlighted by the FDA approval of Inluriyo plus Verzenio in ESR1-mutated ER+/HER2- metastatic breast cancer, where mPFS more than doubled to 11.1 months versus 5.5 months and ORR improved to 35% versus 15% with low discontinuation rates. The company also benefits from an exceptionally strong cardiometabolic franchise, led by Mounjaro with U.S. sales of $13,651 million and a strong rollout supported by 90% commercial/Part D access and capacity expansion, alongside durable contributions from Verzenio, Jardiance, and emerging products such as Ebglyss and Olumiant, which together support the estimated 2025-32 EPS CAGR of 18% that is well above the industry average. Although competition, pricing pressure, and pipeline execution remain meaningful risks, Lilly’s broad portfolio, productive R&D, and expanding launch base create visibility into above-average sales and earnings growth while preserving meaningful upside from additional pipeline successes.

Eli Lilly is facing a fundamentally fragile outlook because its valuation and growth narrative are heavily concentrated in a few large products, especially Mounjaro, Zepbound, and Jardiance, while the excerpt explicitly flags slowing growth across Mounjaro and Zepbound as a major downside risk. The company also carries meaningful development and execution risk, since its pipeline depends on outcomes such as donanemab’s EU approval in 2025 and a cognitively unimpaired Alzheimer’s readout in ~2027, alongside other programs that could be delayed, rejected, or fail, all of which can pressure future revenue visibility. On top of that, the cited risks of intense global competition, intellectual property challenges, pricing pressure, foreign exchange volatility, and sector headwinds from FDA uncertainty or meaningful pharma tariffs suggest that even with strong products and a projected 2027E EPS of $47.00, the business faces multiple fundamental threats to margin durability and long-term earnings quality.